Mateusz Opyrchal, MD, PhD of Roswell Park Cancer Institute discusses how the data from the AURKA study shows a possibility in combination therapy between MAPK pathway and other inhibitors. He states the future of clinical trials will revolve around this type of combination study. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.
Data Shows Possible Combination Therapy with MAPK Pathway and Other Inhibitors
